Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes

Cardiovascular Diabetology

Edith Bigot-Corbel¹  Valentin Blanchard²  Cédric Le May³  Bertrand Cariou³  Matthieu Wargny⁴  Samy Hadjadj⁵  Chloé Chevalier⁵  Mikaël Croyal⁶  Gilles Lambert⁷  Kevin Chemello⁷ 

[1] Department of Biochemistry, CHU Nantes, G et R Laënnec Hospital, Bd Jacques Monod, Nantes, France;Departments of Medicine, Centre for Heart Lung Innovation, Providence Healthcare Research Institute, St. Paul’s Hospital, University of British Columbia, Vancouver, Canada;Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du Thorax, 8 quai Moncousu, 44000, Nantes, France;Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du Thorax, 8 quai Moncousu, 44000, Nantes, France;CHU de Nantes, INSERM CIC 1413, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, Nantes, France;Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du Thorax, 8 quai Moncousu, 44000, Nantes, France;CRNH-Ouest Mass Spectrometry Core Facility, 44000, Nantes, France;Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du Thorax, 8 quai Moncousu, 44000, Nantes, France;Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, 44000, Nantes, France;CRNH-Ouest Mass Spectrometry Core Facility, 44000, Nantes, France;Université de La Réunion, INSERM UMR 1188 DéTROI, Sainte-Clotilde, France;

关键词: New-onset diabetes;    Type 2 diabetes;    Apolipoproteins;    Apolipoprotein E;    IT-Diab study;   

DOI  :  10.1186/s12933-022-01452-5

来源: Springer

【 摘 要 】

BackgroundThe identification of circulating biomarkers associated with the risk of type 2 diabetes (T2D) is useful for improving the current prevention strategies in the most at-risk patients. Here, we aimed to investigate the association of plasma apolipoprotein concentrations in prediabetes subjects with the incidence of new-onset T2D during follow-up.MethodsIn the IT-DIAB prospective study, 307 participants with impaired fasting glucose levels (fasting plasma glucose [FPG]: 110–125 mg/dL) were followed yearly for 5 years. The onset of T2D was defined as a first FPG value ≥ 126 mg/dL during follow-up. Apolipoprotein (apo)A-I, A-II, A-IV, B100, C-I, C-II, C-III, C-IV, D, E, F, H, J, L1, M, and (a) plasma concentrations were determined by mass spectrometry. Correlations between apolipoproteins and metabolic parameters at baseline were assessed by Spearman’s coefficients. Kaplan–Meier curves were drawn using a ternary approach based on terciles and incident T2D. The association between plasma apolipoproteins concentrations and the incidence of T2D was determined using Cox proportional-hazards models.ResultsDuring a median follow-up of 5-year, 115 participants (37.5%) developed T2D. After adjustment for age, sex, body mass index, FPG, HbA1c, and statin use, the plasma levels of apoC-I, apoC-II, apoC-III, apoE, apoF, apoH, apoJ, and apoL1 were positively associated with a high risk for T2D. After further adjustment for plasma triglycerides, only apoE (1 SD natural-log-transformed hazard ratio: 1.28 [95% confidence interval: 1.06; 1.54]; p = 0.010), apoF (1.22 [1.01; 1.48]; p = 0.037), apoJ (1.24 [1.03; 1.49]; p = 0.024), and apoL1 (1.26 [1.05; 1.52]; p = 0.014) remained significantly associated with the onset of T2D. Kaplan–Meier survival curves also showed that the lower third of plasma apoE levels (< 5.97 mg/dL) was significantly associated with a lower risk of conversion to T2D (log-rank test, p = 0.002) compared to the middle and upper thirds.ConclusionsThe plasma apoE levels are positively associated with the risk of T2D in prediabetes subjects, independently of traditional risk factors. The possible associations of apoF, apoJ, and apoL1 with T2D risk also pave the way for further investigations.Trial registration This trial was registered at clinicaltrials.gov as NCT01218061 and NCT01432509

【 授权许可】

CC BY